eFFECTOR Therapeutics Inc
(FRA:LWK)
€
1.07
-0.005 (-0.47%)
Market Cap: 5.14 Mil
Enterprise Value: 345,000.00
PE Ratio: 0
PB Ratio: 5.52
GF Score: 21/100 eFFECTOR Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference Transcript
Sep 26, 2023 / 07:00PM GMT
Release Date Price:
€11.8
(-0.42%)
Lucas Olson Duffy
Cantor Fitzgerald - Analyst
Good afternoon, everyone. Today, I'm here with eFFECTOR Therapeutics. My name is Lucas Olson Duffy. I'm a biotech and biopharma, large cap equity research associate on Louise Chen's team here at Cantor. So just to start off a little, could you introduce yourselves and tell us your roles at eFFECTOR?
Mike Byrnes
eFFECTOR Therapeutics, Inc. - CFO
Sure. Mike Byrnes, I'm the Chief Financial Officer at eFFECTOR. Got about 25 years experience in the industry. Joined eFFECTOR about three years ago.
Mayank Gandhi
eFFECTOR Therapeutics, Inc. - Chief Business Officer
Hi. I'm Mayank Gandhi. I'm the Chief Business Officer. Been at eFFECTOR for about a year and been in the industry for about 20 years or so.
Questions & Answers
Lucas Olson Duffy
Cantor Fitzgerald - Analyst
Wow, that's great. Thank you for the introduction. If we could just get straight into it. Can you tell us a little bit about eFFECTOR top-level view, just
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot